ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting

    Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia

    John S. Sampalis1,2, Mary-Ann Fitzcharles3, Peter A. Ste-Marie4, Emmanouil Rampakakis1,2 and Yoram Shir4, 1JSS Medical Research, Montreal, QC, Canada, 2Jewish General Hospital, McGill University, Montreal, QC, Canada, 3Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, 4Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…
  • Abstract Number: 1624 • 2013 ACR/ARHP Annual Meeting

    Lupus Risk Alleles With High Ethnic Variability Worldwide Are Associated With Renal Disease In Hispanic Patients

    Belinda Waltman1, Kimberly E. Taylor2, Joanne Nititham3 and Lindsey A. Criswell3, 1Department of Medicine, University of California, San Francisco, San Francisco, CA, 2Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 3Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects minority patients. Non-European ancestry is associated with more severe disease, and conversely, European ancestry is associated with a…
  • Abstract Number: 2792 • 2013 ACR/ARHP Annual Meeting

    Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures

    Julia G. Harris1,2, Esi Morgan DeWitt3, Ronald M. Laxer4,5, Stacy P. Ardoin6, Beth S. Gottlieb7, Judyann C. Olson1,2, Murray H. Passo8, Jennifer E. Weiss9, Daniel J. Lovell10, Tzielan C. Lee11, Sheetal S. Vora12,13, Nancy Griffin14, Jason A. Stock15, Lynn M. Darbie14 and Catherine A. Bingham16, 1Medical College of Wisconsin, Milwaukee, WI, 2Children's Hospital of Wisconsin, Milwaukee, WI, 3Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 5Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 6Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 7Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 8Pediatrics, Medical University of South Carolina, Charleston, SC, 9Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, 10Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 11Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, 12University of North Carolina Chapel Hill, Chapel Hill, NC, 13Levine Children's Hospital and Carolinas Medical Center, Charlotte, NC, 14James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 15Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 16Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA

    Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning network designed to improve outcomes of juvenile idiopathic arthritis (JIA) care.  Teams…
  • Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting

    Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience

    Proton Rahman1, Majed M. Khraishi2, William Bensen3, John T. Kelsall4, Brian D. Hanna5, Craig Watts6, Emmanouil Rampakakis7, John S. Sampalis7, May Shawi8, Susan M. Otawa9 and Allen J. Lehman9, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Nexus Clinical Research, St John's, NF, Canada, 3St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 4Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 5Rheumatology, McMaster University, Ontario, Kitchener, ON, Canada, 6Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, 7JSS Medical Research, Montreal, QC, Canada, 8Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
  • Abstract Number: 2641 • 2013 ACR/ARHP Annual Meeting

    Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 2011 Compared To 1995

    Dörte Huscher1, Katinka Albrecht2, Katja Thiele2, Sascha Bischoff2, Jutta G. Richter3, Ina Kötter4, Wolfgang Ochs5 and Angela Zink1, 1German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 4ZIRS, Centre for Interdisciplinary Rheumatology Stuttgart, Stuttgart, Germany, 5Rheumatologist in private practice, Bayreuth, Germany

    Background/Purpose: Compared to rheumatoid arthritis and other arthritis-associated rheumatic diseases, autoimmune connective tissue disorders and vasculitides are still in the early stages of biological therapies.…
  • Abstract Number: 1342 • 2013 ACR/ARHP Annual Meeting

    Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria

    Isabel Castrejón1, Maxime Dougados2, Bernard Combe3, Francis Guillemin4, Bruno Fautrel5 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Cochin Hospital, Paris, France, 3CHU Lapeyronie, Montpellier, France, 4Hopitaux de Brabois, Nancy, France, 5APHP, Pitié-Salpêtrière University Hospital, Paris, France

    Background/Purpose: Different criteria for remission in rheumatoid arthritis (RA) have been developed from a Core Data Set of 7 measures for the DAS28, SDAI, CDAI…
  • Abstract Number: 2536 • 2013 ACR/ARHP Annual Meeting

    Lupus Impact Tracker Is Responsive To Changes In Physician Assessed Disease Status By Systemic Lupus Erythematosus Responder Index

    Hervé Devilliers1,2, Mark Kosinski3, Cindy Garris4 and Meenakshi Jolly5, 1Clinical investigation and clinical epidemiology center (INSERM CIE01), Dijon, France, 2Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, 3QualityMetric Inc, Lincoln, RI, 4US Health Outcomes, GlaxoSmithKline R&D, Research Triangle Park, NC, 5Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Lupus Impact Tracker (LIT) is a 10-item patient reported outcome tool to measure the impact of Systemic Lupus Erythematosus (SLE) or its treatment on…
  • Abstract Number: 1351 • 2013 ACR/ARHP Annual Meeting

    A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA)

    Yoon-Kyoung Sung1,2, Soo-Kyung Cho1,2, Chan-Bum Choi3,4, Soyoung Won5, So-Young Bang6, Hoon-Suk Cha7, Jung-Yoon Choe8, Won Tae Chung9, Seung-Jae Hong10, Jae-Bum Jun4, Hyoun Ah Kim11, Jinseok Kim12, Seong-Kyu Kim8, Tae-Hwan Kim4, Hye-Soon Lee13, Jaejoon Lee7, Jisoo Lee14, Shin-Seok Lee15, Sung Won Lee16, Yeon-Ah Lee10, Seong-Su Nah17, Chang-Hee Suh18, Dae-Hyun Yoo4, Bo Young Yoon19 and Sang-Cheol Bae1,2, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 5Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Hanyang University Guri Hospital, Guri, South Korea, 7Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 8Catholic University of Daegu School of Medicine, Daegu, South Korea, 9Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, 10Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, 11Ajou University Hospital, Suwon, South Korea, 12Division of Rheumatology, Internal Medicine, Jeju National University Hospital, Jeju, Korea, South Korea, 13Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, 14Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, 15Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, 16Rheumatology, Dong-A University Hospital, Busan, South Korea, 17Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, 18Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, 19Inje University Ilsan Paik Hospital, Goyang, South Korea

    Background/Purpose: The results from RCTs may not be generalizable to clinical practice because of their inclusion and exclusion criteria. Instead, observational cohorts and registries might…
  • Abstract Number: 2292 • 2013 ACR/ARHP Annual Meeting

    Factors Affecting The Discrepancy Between Physician and Patient Global Assessment Of Disease Activity In Early and Established Rheumatoid Arthritis Patients- Results From The Ontario Best Practices Initiative

    Pooneh Akhavan1, Binu Jacob2, Edward C. Keystone3,4, Xiuying Li5, J. Carter Thorne6 and Claire Bombardier7, 1Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto General Research Institute, Toronto, ON, Canada, 3Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, 4University of Toronto/Mount Sinai Hospital, Toronto, ON, Canada, 5Clinical Decision Making and Health Care, University Health Network, Toronto, ON, Canada, 6Southlake Regional Health Centre, Newmarket, ON, Canada, 7Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Discrepancy between patient (PGA) and physician (MDGA) global assessments in Rheumatoid Arthritis (RA) can adversely affect therapeutic decisions. The pattern of PGA and MDGA,…
  • Abstract Number: 1264 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of Quality Indicators and Disease Damage In Childhood-Onset Systemic Lupus Erythematosus Patients

    Julia G. Harris1,2, Kristyn I. Maletta3, Evelyn M. Kuhn3 and Judyann C. Olson1,2, 1Medical College of Wisconsin, Milwaukee, WI, 2Children's Hospital of Wisconsin, Milwaukee, WI, 3National Outcomes Center, Children's Hospital of Wisconsin, Milwaukee, WI

    Background/Purpose:   Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect virtually every organ system and may lead to significant morbidities.  A…
  • Abstract Number: 2300 • 2013 ACR/ARHP Annual Meeting

    Rheumatologists Who Are Consistently Using An Objective Outcome Instrument Do Not “Treat To Target” In a Real World Setting

    Gary Craig1,2, Howard Kenney1,2, Keith Knapp2 and Sergio Schwartzman3, 1Arthritis Northwest PLLC., Spokane, WA, 2T3 JointMan LLC., Spokane, WA, 3Rheumatology, Hosp for Special Surgery, New York, NY

    Background/Purpose: The public database JointManTMwas launched January 2012 with a mission to provide a practical outcome tool to manage patients with RA in a clinical…
  • Abstract Number: 968 • 2013 ACR/ARHP Annual Meeting

    Success Of Educational Intervention In Improving The Management Of Rheumatoid Arthritis

    Nimish Mehta and Ronald Viggiani, Medscape, LLC, New York, NY

    Background/Purpose: In many patients with rheumatoid arthritis (RA), the disease is not adequately controlled and only a minority of patients attain the goal of consistent…
  • Abstract Number: 2238 • 2013 ACR/ARHP Annual Meeting

    Comparison Of The Long-Term Outcome For Rheumatoid Arthritis Patients With  persistent Moderate Disease Activity Or Disease Remission During The First Year After Diagnosis: Data From The Espoir Cohort

    Bernard Combe1, Isabelle Logeart2, M. Belkacemi3, S Dadoun4, Jean-Pierre Daurès5 and Maxime Dougados6, 1Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, 2Pfizer, Paris, France, 3CHRU Montpellier, Montpellier, France, 4Paris-Pitié Salpêtrière University Hospital, Paris, France, 5Service BESPIM, CHU, Nimes, France, 6Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France

    Background/Purpose: The Treat to Target and EULAR recommendations highlighted the need for achieving and maintaining remission in patients with early RA. We investigated if early…
  • Abstract Number: 763 • 2013 ACR/ARHP Annual Meeting

    The Risk Of Myocardial Infarction In Systemic Sclerosis: A Population-Based Cohort Study

    Iman Hemmati1, Hyon K. Choi2,3, Kamran Shojania3,4, Eric C. Sayre3 and J. Antonio Avina-Zubieta3,5, 1Deparment of Medicine and Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Rheumatology, University of British Columbia, Vancouver, BC, Canada, 5Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada

    Background/Purpose: An increased risk of premature atherosclerosis has been well described in patients with rheumatoid arthritis and systemic lupus erythematosus. However, there is limited data…
  • Abstract Number: 2245 • 2013 ACR/ARHP Annual Meeting

    Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative

    Pooneh Akhavan1, Binu Jacob2, Paul R. Fortin3, George A. Tomlinson4 and Claire Bombardier5,6, 1Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto General Research Institute, Toronto, ON, Canada, 3University of Laval, Quebec, QC, Canada, 4Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, 5Rheumatology, University of Toronto, Toronto, ON, Canada, 6Division of rheumatology and Department of Health Policy, Management, and Evaluation, University Health Network, Toronto, ON, Canada

    Background/Purpose: Patient reported outcome measures (PROM) are used in routine practice for assessment of disease activity. They have been shown to correlate well with other…
  • « Previous Page
  • 1
  • …
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology